Table 5.
Effect of early therapy on growth outcomes in children with Crohn’s disease.
| Growth parameter | Early anti-TNF [n = 135; 41%] |
No early anti-TNF [n = 196; 59%] | Total [n = 331] |
p-valuea |
|---|---|---|---|---|
| HFA Z-score at diagnosis, mean [SD] | 130/135 -0.06 [1.10] |
190/196 -0.11 [1.31] |
320/331 -0.09 [1.19] |
0.7 |
| BMI Z-score at diagnosis, mean [SD] | 129/135 -1.21 [1.48] |
190/196 -0.79 [1.50] |
319/331 -0.96 [1.51] |
0.01 |
| ΔHFA Z-score by 1 year, mean [SD]b | 104/135 +0.05 [0.39]; p = 0.16 |
145/196 +0.01 [0.59]; p = 0.80 |
249/331 +0.03 [0.50]; p = 0.33 |
0.56 |
| ΔHFA Z-score by 2 years, mean [SD]b | 37/72 +0.15 [0.62] p = 0.09 |
83/121 +0.20 [0.60] p = 0.009 |
120/192 +0.18 [0.60]; p = 0.002 |
0.65 |
| ΔBMI Z-score by 1 year, mean [SD]b | 100/135 +1.18 [1.05]; p <0.001 |
142/196 +0.88 [1.07]; p <0.001 |
242/331 +1.03 [1.07]; p <0.001 |
0.02 |
| ΔBMI Z-score by 2 years, mean [SD]b | 35/71 +1.41 [1.30]; p <0.001 |
81/121 +1.05 [1.07]; p <0.001 |
116/192 +1.21 [1.19]; p <0.001 |
0.11 |
scores were obtained by standardising growth parameters using the WHO Growth Reference standards.
TNF, tumour necrosis factor; SD, standard deviation; HFA, height for age; BMI, body mass index.
aIndependent two-sample t test.
bPaired sample t test.